SCHEMBL4874970

SCHEMBL4874970

CCCCCCc1ccc(S(=O)(=O)Nc2ccc(SC3CCN(C)CC3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.56
DRD3 P35462 7/20 0.56
HTR6 P50406 5/20 0.56
HTR2A P28223 4/20 0.56
HTR2C P28335 4/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
FFAR1 O14842 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
MLNR O43193 3/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 2/20 0.50
NMT1 P30419 6/20 0.49
ALDH1A1 P00352 1/20 0.47
GHSR Q92847 1/20 0.46
KCNH2 Q12809 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874044 0.87 ALDH1A1 (0.62) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL4874458 0.81 ALDH1A1 (0.44) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL4866321 0.81 ALDH1A1 (0.57) LMNATP53ALDH1A1MAPT
SCHEMBL4873695 0.80 ALDH1A1 (0.58) HTR2AHTR2CCYP3A4CYP2C9TP53
SCHEMBL4876689 0.80 CES1 (0.54) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL4876385 0.80 HTR6 (0.49) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL4876786 0.78 ALDH1A1 (0.56) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL6617076 0.78 ALDH1A1 (0.60) LMNAALDH1A1MAPT
SCHEMBL7151939 0.78 FFAR1 (0.78) DRD2DRD3HTR6HTR2AHTR2C
SCHEMBL4876622 0.78 ALDH1A1 (0.60) CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 US disclosed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 DRD2 437/4885DRD3 890/4885HTR6 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.